Endotronix begins heart failure study with Cordella Sensor
Digital health and medical technology firm Endotronix has recruited the first two patients in the PROACTIVE-HF pivotal trial of the Cordella pulmonary artery (PA) pressure sensor system.
The pre-market investigational device exempt (IDE) trial has been designed to assess the safety and efficacy of the Cordella pressure sensor system to treat chronic heart failure (HF).
The Cordella heart failure system delivers a comprehensive health status of the patient at home with advanced tools, which collect and share health data with healthcare providers for trend-based management. The Cordella Sensor incorporates PA pressure data into the Cordella system.
In the trial, the first two patients have been implanted with the Cordella Sensor by Dr Navin Kapur and Michael Kiernan at Tufts Medical Center in Boston of Massachusetts and Dr Liviu Klein at the University of California San Francisco (UCSF).
